Benzalkonium chloride contraceptive gel capable of killing AIDS pathogens and preparation method of benzalkonium chloride contraceptive gel
By using modified cyclodextrin and amino acid grafting technology, combined with arginine and cysteine, and optimizing the grafting process, the problems of slow inactivation speed and short mucosal retention time of benzalkonium chloride contraceptive gel against HIV pathogens have been solved. This has achieved rapid and efficient virus inactivation and long-lasting mucosal adhesion, providing dual protection.
Patent Information
- Application Number
- CN202610781115.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-06-02
- Publication Date
- 2026-07-14
AI Technical Summary
Existing benzalkonium chloride contraceptive gels have a slow inactivation rate against HIV pathogens, a short mucosal retention time, and low drug utilization, making them unable to quickly and efficiently kill HIV pathogens and provide a lasting protective barrier during sexual intercourse.
Modified cyclodextrin was used to generate aldehyde groups by oxidizing γ-cyclodextrin with sodium periodate, which then reacted with amino acids to form imine bonds. These imine bonds were then reduced to secondary amine bonds with sodium borohydride. The amino acids were grafted onto the cyclodextrin backbone. Combined with arginine and cysteine, the stepwise grafting process was optimized to improve mucosal adhesion and virus inactivation efficiency by utilizing the synergistic effect of electrostatic adsorption and thiol group disruption of the viral envelope.
It significantly improves the instantaneous inactivation rate and mucosal retention performance of benzalkonium chloride gel against HIV pathogens, achieving a dual protective effect of rapid and efficient virus clearance and long-lasting physical barrier.